冠脉宁联合常规治疗对冠心病的系统评价

目的系统评价冠脉宁联合常规治疗对冠心病的疗效。方法计算机检索Cochrane图书馆（2013年第2期）、EMBase、PubMed、中国期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、中文科技期刊全文数据库（vIP）（各数据库检索时间均从创建至2013年3月）关于冠脉宁联合常规治疗对冠心病的随机对照试验。2名数据员按纳入与排除标准独立筛选试验，并对纳入研究的方法学质量进行评价，提取资料，用RevMan 5．14软件对数据进行Meta分析。结果共纳入6篇RCT，包括725例患者。Meta分析结果显示，与对照组相比，冠脉宁组临床有效率优于常规治疗组[RR=5．87，95％CI（3．45，9．99），P〈0．00001]；冠脉宁组心电图改善率优于常规治疗组[RR=2，95％CI（1．33，3．02），P〈0．00001]，差异均有统计学意义。结论基于现有临床证据，冠脉宁联合常规治疗对冠心病有效，安全性好。但由于纳入研究数量较少，研究质量不统一，本结论尚需要更多大样本、高质量临床随机对照试验予以证实。

Guanmaining Combined Conventional Treatment for Coronary Heart Disease: A Systematic Review

OBJECTIIVE To evaluate the effectiveness and safety of Guanmaining combined conventional treatment for coronary heart disease. METHODS The Cochrane Library (Issue 2, 2013), EMbase, PubMed, CBM, CNKI and VIP(from their inception to Match 2013) for RCTs of Guanmaining combined conventional treatment for coronary heart disease were searched. Two reviewers independently retrieved RCTs according to the inclusion and exclusion criteria, assessed the methodological quality of included trials, and extracted data. The data analyses was performed by RevMan 5.14 software. RESULTS Six RCTs involving 725 patients were ultimately identified. The results of meta-analyses showed that symptoms improved effective rate of Guanmaining group was superior to control group[RR=5.87, 95%CI(3.45, 9.99), P<0.000 01]; ECG improved effective rate of Guanmaining group was superior to control group[RR=2, 95%CI(1.33, 3.02), P<0.000 01], and there were significant differences. CONCLUSION The results of meta-analyses indicate that Guanmaining combined conventional treatment for coronary heart disease is effective and safety. Howerver, due to the number and quality of included studies, more large sample size, high-quality RCTs are needed.